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Inflammation

Septic shock results from an uncontrolled inflammatory response, mediated primarily by LPS. Cholesterol transport plays
an important role in the host response to LPS, as LPS is neutralized by lipoproteins and adrenal cholesterol uptake is
required for antiinflammatory glucocorticoid synthesis. In this study, we show that scavenger receptor B-I (SR-BI), an HDL
receptor that mediates HDL cholesterol ester uptake into cells, is required for the normal antiinflammatory response to
LPS-induced endotoxic shock. Despite elevated plasma HDL levels, SR-BI–null mice displayed an uncontrollable
inflammatory cytokine response and a markedly higher lethality rate than control mice in response to LPS. In addition,
SR-BI–null mice showed a lack of inducible glucocorticoid synthesis in response to LPS, bacterial infection, stress, or
ACTH. Glucocorticoid insufficiency in SR-BI–null mice was due to primary adrenal malfunction resulting from deficient
cholesterol delivery from HDL. Furthermore, corticosterone supplementation decreased the sensitivity of SR-BI–null mice
to LPS. Plasma from control and SR-BI–null mice exhibited a similar ability to neutralize LPS, whereas SR-BI–null mice
showed decreased plasma clearance of LPS into the liver and hepatocytes compared with normal mice. We conclude
that SR-BI in mice is required for the antiinflammatory response to LPS-induced endotoxic shock, likely through its
essential role in facilitating glucocorticoid production and LPS hepatic clearance.
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SR-BI protects against endotoxemia
in mice through its roles in glucocorticoid
production and hepatic clearance
Lei Cai, Ailing Ji, Frederick C. de Beer, Lisa R. Tannock,
and Deneys R. van der Westhuyzen
Division of Endocrinology and Molecular Medicine, Department of Internal Medicine, Cardiovascular Research Center, and
Graduate Center of Nutritional Sciences, University of Kentucky Medical Center, Lexington, Kentucky, USA.
Veterans Affairs Medical Center, Lexington, Kentucky, USA.

Septic shock results from an uncontrolled inflammatory response, mediated primarily by LPS. Cholesterol
transport plays an important role in the host response to LPS, as LPS is neutralized by lipoproteins and adrenal
cholesterol uptake is required for antiinflammatory glucocorticoid synthesis. In this study, we show that scavenger receptor B-I (SR-BI), an HDL receptor that mediates HDL cholesterol ester uptake into cells, is required
for the normal antiinflammatory response to LPS-induced endotoxic shock. Despite elevated plasma HDL
levels, SR-BI–null mice displayed an uncontrollable inflammatory cytokine response and a markedly higher
lethality rate than control mice in response to LPS. In addition, SR-BI–null mice showed a lack of inducible
glucocorticoid synthesis in response to LPS, bacterial infection, stress, or ACTH. Glucocorticoid insufficiency in SR-BI–null mice was due to primary adrenal malfunction resulting from deficient cholesterol delivery
from HDL. Furthermore, corticosterone supplementation decreased the sensitivity of SR-BI–null mice to LPS.
Plasma from control and SR-BI–null mice exhibited a similar ability to neutralize LPS, whereas SR-BI–null
mice showed decreased plasma clearance of LPS into the liver and hepatocytes compared with normal mice. We
conclude that SR-BI in mice is required for the antiinflammatory response to LPS-induced endotoxic shock,
likely through its essential role in facilitating glucocorticoid production and LPS hepatic clearance.
Introduction
Endotoxic shock remains a significant cause of death despite
the use of various therapeutic approaches (1). LPS is the primary
cause of Gram-negative sepsis. LPS, through its interaction with
the LPS-binding protein–containing (LBP-containing) LBPCD14-TLR4 complex, activates macrophages, causing the release
of inflammatory cytokines (2). While the inflammatory response
represents a host defense to invading pathogens, uncontrolled
systemic inflammation can lead to serious systemic complications such as disseminated intravascular coagulation, tissue damage, and endotoxic shock (2).
LPS can be neutralized by the major lipoproteins, HDL, LDL,
VLDL, and chylomicrons as well as apolipoproteins apoE and apoA-I
(3–5). apoE may protect by redirecting LPS from Kupffer cells to
hepatocytes (3). The preferential binding of LBP to HDL accounts
for HDL being the primary carrier of LPS in the blood (6). While
LPS is cleared mainly by hepatocytes, the mechanism or mechanisms are unclear. Although scavenger receptor A (SR-A) has been
reported to mediate LPS uptake and detoxification (7), SR-A–null
mice showed unchanged production of TNF-α in response to LPS
(8), casting doubt on the physiological role of SR-A in sepsis. These
findings suggest the involvement of other scavenger receptors, such
as scavenger receptor B-I (SR-BI), in LPS metabolism.
Nonstandard abbreviations used: CE, cholesterol ester; Cyp11A1, cytochrome
P450 side-chain cleavage enzyme; LAL, Limulus amebocyte lysate; LBP, LPS-binding
protein; LDLR, LDL receptor; MCP-1, monocyte chemoattractant protein-1; Q-PCR,
quantitative real-time PCR analysis; SR-A, scavenger receptor A; SR-BI, scavenger
receptor B-I; StAR, steroidogenic acute regulatory protein.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 118:364–375 (2008). doi:10.1172/JCI31539.
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SR-BI is an HDL receptor that plays a key role in the reverse
cholesterol transport pathway through mediating selective lipid
uptake from HDL particles (9, 10). SR-BI in the liver is highly
expressed in hepatocytes (9) and to a lesser extent in Kupffer cells
(11) and functions to clear HDL cholesterol into the bile (12).
Studies using SR-BI–deficient and –transgenic mice have shown
that SR-BI is protective against atherosclerosis (10). SR-BI has a
broad ligand-binding specificity and is involved in the binding and
cellular uptake of various endogenous ligands, such as β-amyloid
and serum amyloid A (13), apoptotic cells, and exogenous pathogens (10). For example, SR-BI plays a role as a receptor for hepatitis C virus and is required for virus infection (14). Importantly,
SR-BI also mediates the binding and uptake of LPS (15), the major
Gram-negative bacterial cell wall component, in macrophages and
HeLa cells overexpressing SR-BI, and lipoteichoic acid (LTA) (16),
a component of Gram-positive bacteria. Furthermore, SR-BI and
its alternatively spliced variant, SR-BII (17), have been shown to
directly bind a variety of bacteria with little discrimination, suggesting a conserved role for these receptors in pattern recognition and innate immunity (18). This is supported by the fact that
SR-BI–null mice are more susceptible to LPS-induced death, a
finding attributed to a protective effect of SR-BI in inhibiting NOinduced cell toxicity (19). A recent study, however, reported that
SR-BI facilitates bacterial invasion and proliferation in cells, with
evasion of lysosomal processing (16), indicating that SR-BI might
facilitate bacterial infection and sepsis.
SR-BI is highly expressed in the adrenals, ovary, and testis, where
it functions to provide cholesterol for steroid hormone synthesis
through the selective cholesterol ester (CE) uptake from HDL and
LDL (20–22). Although the LDL receptor (LDLR) also contributes
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Figure 1
Hyperinflammatory response in SR-BI–/– mice challenged
with LPS. SR-BI–/– and SR-BI+/+ mice were injected i.p. with
0.5 μg/g body weight of LPS. Plasma TNF-α and IL-6 levels
were determined by ELISA (A and B). Liver TNF-α and IL-6
mRNA levels were determined by Q-PCR (C and D). Values shown are the mean ± SD (n = 3). Similar results were
found in 4 independent experiments.

to cholesterol delivery through LDL uptake (23), SR-BI–mediated
HDL cholesterol uptake appears to be the major source of cholesterol for glucocorticoid synthesis in rodents (20, 24, 25). A critical role of SR-BI in humans is suggested by the observation that
patients with familial hypercholesterolemia that lack functional
LDLR show a normal response to ACTH (26). Glucocorticoids
exert antiinflammatory effects by suppressing proinflammatory
cytokines (e.g. TNF-α, IL-1, IL-6) and stimulating antiinflammatory mediators (IL-10, TGF-β) (27). Adrenal deficiency, characterized
by glucocorticoid insufficiency, is often associated with sepsis (28).
Common causes of adrenal failure are impaired function of the
upstream hypothalamic-pituitary-adrenal axis (secondary adrenal insufficiency) and malfunction or destruction of the adrenal
glands (primary adrenal insufficiency). Since only small amounts
of glucocorticoids are stored in the adrenals (29), primary adrenal
failure in endotoxic shock is usually due to insufficient glucocorticoid biosynthesis (29). Depletion of plasma HDL in apoA-I–null
mice (30) or by inactivation of SR-BI (31) markedly reduces CE
content in the adrenals. In the case of apoA-I–null mice, adrenal
function was affected and corticosterone production was limited
(30). In SR-BI–null mice, adrenal function appeared unaffected
under normal physiological conditions (10).
In this study, we have investigated the role of SR-BI in regulating LPS-induced inflammation and endotoxic shock. Studies using
control and SR-BI–null mice have shown that SR-BI expression is
essential for stimulated glucocorticoid production in the adrenals
in response to LPS and stress, and that glucocorticoid insufficiency
as well as reduced LPS clearance likely contribute to the enhanced
inflammation and endotoxin-induced death in SR-BI–null mice.
Results
SR-BI–null mice show an exaggerated inflammatory response to LPSinduced endotoxic shock. To determine the influence of SR-BI on
LPS-induced inflammation, SR-BI–null and control mice were
injected i.p. with LPS (0.5 μg/g body weight), and serum cytokine
levels were determined by ELISA at various times following injection. As shown in Figure 1, LPS resulted in a strong induction
of both TNF-α and IL-6. In the case of TNF-α, maximum concentrations were reached by 2 hours and were markedly higher
in the SR-BI–null mice than in control mice (Figure 1A). In the

case of IL-6, LPS-induced plasma concentrations reached nearly
similar maximal levels in both SR-BI–null and control mice after
2 hours (Figure 1B). However, IL-6 levels in control mice returned
to baseline levels after 8 hours, whereas the level of IL-6 in SR-BI–
null mice remained elevated for 24 hours before dropping to baseline levels by 48 hours. An increased TNF-α and IL-6 cytokine
response in SR-BI–null mice compared with control mice was
evident at each LPS concentration tested, and no cytokine induction was observed in mice injected with saline alone (data not
shown). TNF-α and IL-6 expression in the livers of these mice were
assessed by quantitative real-time PCR analysis (Q-PCR) of mRNA
levels. In line with the observed differences in protein expression,
SR-BI–null mice had higher expression of liver mRNA for both
TNF-α and IL-6 in response to LPS than control mice (Figure
1, C and D). However, the lack of close correlation between liver
mRNA levels and plasma cytokine levels suggests posttranscriptional regulation mechanisms and/or the contribution of nonhepatic cytokine production.
A cytokine array analysis of plasma at either 2 or 24 hours after
LPS injection showed that the levels of a variety of proinflammatory cytokines were increased to a significantly greater extent in
SR-BI–null mice compared with control mice (Table 1). Cytokines
that showed no difference between SR-BI–null and control mice
at 2 hours are also listed in Table 1. Of these, IL-5, IL-6, and IL-10
levels were significantly greater in SR-BI–null mice at 24 hours,
whereas the remainder showed no difference at 24 hours (data not
shown). Of all the cytokines assayed, IL-4, IL-7, IL-13, and IL-15
did not show any response to LPS in either of the 2 genotypes.
These are Th2 cytokines associated with allergy, autoimmune disease, and parasitic infection. Under basal conditions in the absence
of LPS, no differences in cytokine levels were observed between
SR-BI–null and control mice. These data clearly show that SR-BI–
null mice exhibit a markedly increased inflammatory response to
LPS compared with control SR-BI+/+ mice.
An overproduction of proinflammatory cytokines caused by LPS
in SR-BI–null mice suggests increased susceptibility to endotoxic
shock and death in these animals. Consistent with this hypothesis,
we observed a marked difference in survival rate of SR-BI–null and
control mice injected i.p. with a single relatively moderate dose of
LPS (5 μg/g body weight) (Figure 2). Neither the control group
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Table 1
Cytokine levels in SR-BI+/+ and SR-BI–/– mice in response to LPS
Cytokine
(pg/ml)

SR-BI+/+

SR-BI–/–

SR-BI+/+/LPS

SR-BI–/–/LPS

Cytokines showing differences between SR-BI–/– and SR-BI+/+ mice
Two hours after LPS injection
GM-CSF
IL-1β
IL-9
IL-12
MIP
RANTES
TNF-α

17 ± 14
<3.2
12 ± 10
40 ± 35
32 ± 31
5.9 ± 4.0
<3.2

13 ± 10
<3.2
16 ± 13
20 ±10
30 ± 27
5.2 ± 2.0
<3.2

146 ± 22
17 ± 4.5
28 ± 8.0
80 ± 14
4778 ± 267
70 ± 33
248 ± 50

332 ± 120A
47 ± 12A
47 ± 12A
115 ± 5.0A
8439 ± 270A
397 ± 186B
864 ± 385B

20 ± 26
375 ± 127
17 ± 0.7
183 ± 68
471 ± 206

171 ± 76B
8432 ± 2716B
225 ± 88B
6063 ± 3937A
4744 ± 798B

Twenty-four hours after LPS injection
IL-5
IL-6
IL-10
KC
MCP-1

4.3 ± 1.6
14 ± 8.0
<3.2
39 ± 11
18 ± 16

4.0 ± 1.0
10 ± 4.5
<3.2
28 ± 7.6
14 ± 18

Cytokines not showing difference between SR-BI–/– and SR-BI+/+ mice
Two hours after LPS injection
IFN-γ
IL-1α
IL-2
IL-4
IL-5
IL-6
IL-7
IL-10
IL-13
IL-15
IL-17
IP-10

<3.2
16 ± 5
<3.2
<3.2
4.0 ± 1.0
26 ± 12
<3.2
<3.2
110 ± 94
43 ± 38
9.1 ± 5.3
183 ± 96

<3.2
7.1 ± 5.2
<3.2
<3.2
5.3 ± 1.6
14 ± 6
<3.2
<3.2
129 ± 80
36 ± 31
4.4 ± 1.7
183 ± 77

18.4 ± 5.4
443 ± 84
6.2 ± 1.9
<3.2
14.2 ± 6.4
>10000
<3.2
654 ± 385
242 ± 85
49 ± 11
16.5 ± 0.6
1441 ± 435

14.9 ± 16.8
302 ± 126
8.2 ± 5.9
<3.2
2.5 ± 2.3
>10000
<3.2
541 ± 96
252 ± 50
45 ± 8
30 ± 14
1337 ± 662

SR-BI–/– and SR-BI+/+ mice were injected i.p. with saline or 0.5 μg/g body
weight LPS (SR-BI+/+/LPS and SR-BI–/–/LPS). Mice were sacrificed after
2 or 24 hours (as indicated). Serum was analyzed by cytokine protein
array (multiplex biomarker assay using xMAP technology). In the case
of 4 cytokines, IL-6, MCP-1, G-CSF, and keratinocyte derived chemokine (KC), measured on the same array, levels were markedly induced
by LPS treatment and at 2 hours exceeded 10,000 pg/ml and were not
quantifiable. IL-6 was not significantly different between the 2 groups as
shown by ELISA in Figure 1. MCP-1 at 2 hours was significantly different
between the 2 groups when treated with a lower dose of LPS (0.125 μg/g
body weight) as shown by ELISA in Figure 6. KC was significantly greater
at 24 hours in SR-BI–null mice than in control mice (Table 1A). Values
shown are the mean ± SD (n = 3). AP < 0.05; BP < 0.01, SR-BI+/+/LPS vs.
SR-BI–/–/LPS. Similar results were found in 2 independent experiments.
IP-10, interferon-inducible protein 10.

nor the SR-BI heterozygous (+/–) group had any fatalities (n = 8),
whereas there was a 100% fatality rate within 3 days in the SR-BI–
null group (n = 8). The SR-BI–null mice showed symptoms of stress,
including reduced movement, shivering, and diarrhea, whereas
both the control mice and heterozygous mice appeared free of
these symptoms. As was the case for mice treated with 0.5 μg/g
body weight of LPS (Figure 1 and Table 1), SR-BI–null mice treated
with the higher dose of LPS (5 μg/g body weight) showed markedly
enhanced plasma levels of TNF-α at 2 hours compared with the
control mice, whereas IL-6 levels were induced to the same extent
in the 2 mouse groups at the same time point (Figure 2B).
366

Glucocorticoid insufficiency in SR-BI–null mice during LPS-induced
inflammation. Glucocorticoids play an important regulatory role in
the inflammatory response, and since SR-BI–dependent uptake of
cholesterol into the adrenal is thought to be important in providing cholesterol for glucocorticoid synthesis, we evaluated adrenal
function in SR-BI–null mice during LPS-induced inflammation.
As demonstrated in Figure 3A, plasma corticosterone levels in
control mice were markedly increased (3- to 4-fold) in response to
LPS in a dose-dependent manner. Mice lacking CD36 (CD36–/–),
a class B scavenger receptor closely related to SR-BI but which
does not mediate efficient CE uptake from HDL (32), showed a
similar corticosterone response to controls. In SR-BI–null mice,
however, plasma corticosterone levels were completely unaltered
during LPS-induced inflammation, indicating adrenal glucocorticoid insufficiency. A lack of corticosterone induction was also
seen in SR-BI–null mice treated with the higher doses of LPS of
5 μg/g body weight (plasma corticosterone levels [ng/ml]: SR-BI+/+,
124.3 ± 25.5 vs. SR-BI+/+ plus LPS, 1012.7 ± 97, P < 0.05; SR-BI–/–,
101 ± 40 vs. SR-BI–/– plus LPS, 118 ± 53.5, P > 0.05). To determine
whether this glucocorticoid insufficiency directly contributes to
the increased mortality observed in SR-BI–null mice challenged
with LPS, we tested the effect of corticosterone supplementation
through the drinking water on survival rates in mice challenged
with LPS. In the case of control mice, no deaths were observed in
either the corticosterone-treated or untreated groups (Figure 3B).
However, corticosterone supplementation through the drinking
water markedly improved the survival rate in SR-BI–null mice,
albeit not to the 100% survival rate seen in the control groups.
Corticosterone supplementation significantly increased plasma
corticosterone levels in SR-BI–null mice such that levels measured
in surviving SR-BI–null mice and control mice were similar at 66
hours and exceeded those in unsupplemented control mice (Figure
3C). Supplementation with corticosterone also markedly reduced
LPS-induced TNF-α levels in both SR-BI–null and control mice
treated with LPS at either a low (0.5 μg/g body weight) or higher
dose (5 μg/g body weight), although in supplemented SR-BI–null
mice at the high LPS dose, TNF-α levels remained at higher levels
than in control mice (Figure 3D). Corticosterone did not simply
delay the onset of septic shock, since the surviving mice appeared
to be recovering from LPS treatment judged on the basis of the
physical signs, which included improved activity, normal breathing, and lack of shivering. In addition, in surviving mice, the levels
of TNF-α and IL-6 were reduced to baseline or near baseline levels
(less than 1 ng/ml) at the end of the experiments.
To determine whether the lack of glucocorticoid response in SR-BI–
null mice is due to altered ACTH production by the pituitary or to
a more direct effect at the level of the adrenal, we first compared
plasma ACTH levels in both LPS-treated and control mice. ACTH
levels in SR-BI–null mice and control mice were similar under basal
conditions and increased significantly in response to LPS (Figure
4A). To investigate whether the decreased corticosterone level in
the SR-BI–null mice was due to decreased responsiveness of the
adrenal to ACTH stimulation, mice were injected s.c. with ACTH
(Figure 4B). A maximal corticosterone level in control mice was
achieved at a dose of 1 unit of ACTH, and no further increase was
seen with doses up to 8 units of ACTH (data not shown). SR-BI–
null mice, unlike control mice, failed to respond to ACTH over a
5-hour period following injection with 2 units of ACTH (Figure
4B) or 4 units of ACTH (data not shown). Interestingly, insufficient corticosterone production was not only found in the inflam-
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Figure 2
SR-BI–/– mice are more sensitive to LPS-induced lethality. (A) Survival
of SR-BI–/– mice in response to LPS. SR-BI–/–, SR-BI+/–, and SR-BI+/+
mice (n = 8) were injected i.p. with 5 μg/g body weight of LPS. Mice
were carefully monitored, and survival rates at the indicated times
were recorded (SR-BI–/– vs. SR-BI+/+; P < 0.001). (B) Plasma cytokine
levels in SR-BI–/– and SR-BI+/+ mice challenged with LPS. LPS (5 μg/g
body weight) was injected i.p. into SR-BI+/+ and SR-BI–/– mice, and
blood was collected 2 hours following LPS injection. Plasma IL-6 and
TNF-α levels were determined by ELISA. Values shown are the mean
± SD (n = 4) (*P < 0.05; **P < 0.01). Similar results were seen in 3
independent experiments.

matory response but also resulted from the stress of a 5°C swim
(Figure 4C). These experiments indicate that adrenal insufficiency
occurred not only under severe acute phase response conditions
but also following a common physical/mental stress challenge.
To relate our findings on the response of SR-BI–null and control
mice to bacterial infection, we assessed the inflammatory response
and adrenal function in SR-BI–null mice challenged with Gramnegative bacteria Escherichia coli. As shown in Figure 5, 2 hours following an E. coli challenge, plasma levels of TNF-α and monocyte
chemoattractant protein-1 (MCP-1) were each significantly elevated in SR-BI–null mice compared with the control mice (Figure 5A).
At the same time, plasma corticosterone levels were markedly lower
following E. coli exposure in SR-BI–null mice than in control mice
(Figure 5B). Cytokine levels and plasma corticosterone levels were
similarly low in untreated SR-BI–null and control mice (data not
shown). These results clearly indicate that SR-BI deficiency results
in an increased inflammatory response following E. coli infection.
Adrenal insufficiency contributes to an enhanced inflammatory
response and endotoxic shock in SR-BI–null mice. To further investi-

gate the role of the adrenals in the LPS-induced inflammatory
response, both control and SR-BI–null mice were adrenalectomized and then treated 7 days after recovery with LPS. It should
be noted that adrenalectomy renders mice deficient, not only in
corticosterone, but also in other adrenal hormones that may each
have a role in inflammation (33). LPS was used at a relatively low
dose (0.125 μg/g body weight) since adrenalectomy increases sensitivity in mice to inflammation (34). Prior to LPS injection, basal
levels of both TNF-α and MCP-1 were similarly low in control and
SR-BI–null mice (data not shown). In the sham-operated SR-BI–
null mice, there was an inflammatory response to LPS such that
the levels of TNF-α, IL-6, and MCP-1 were markedly greater than
the corresponding levels in control SR-BI+/+ mice 2 hours following LPS injection (Figure 6, A–C). A greater inflammatory
response to LPS was observed in the adrenalectomized mice from
both groups. In the case of TNF-α, levels were approximately 38%
higher (P < 0.05) in the adrenalectomized SR-BI–null mice than
in control mice (Figure 6A). However, no differences in either IL-6
or MCP-1 levels were observed between adrenalectomized SR-BI–
null and control mice under conditions in which the levels of the
2 cytokines were both extremely high (Figure 6, B and C). The
differences observed in IL-6 and MCP-1 levels between shamoperated control and SR-BI–null mice treated with LPS were not
observed in the experiments shown in Figure 1B and Table 1.
This difference is likely related to the lower dose of LPS used in
the experiment shown in Figure 6. Thus, while cytokine levels in

Figure 3
Plasma corticosterone levels are not induced in SR-BI–/–
mice challenged with LPS. (A) Corticosterone levels in
SR-BI–/– and CD36–/– mice injected with various amounts
of LPS (0.17, 0.5, and 1.5 μg/g body weight) and sacrificed 2 hours later. Values shown are the mean ± SD
(n = 4). a, b, c, P < 0.05. (B) SR-BI–/– and SR-BI+/+ mice
were given corticosterone (100 μg/ml in 0.1% ethanol) in
drinking water (SR-BI–/–/C, SR-BI+/+/C) or 0.1% ethanol
only 8 hours prior to i.p. injection of LPS (5 μg/g body
weight). Survival rates at the indicated times following
LPS administration are shown (n = 7). (C) Plasma corticosterone levels in the surviving mice. Surviving mice
were sacrificed 66 hours after LPS challenge. Values
shown are the mean ± SD (n = 4 for SR-BI–/–; n = 7 for
SR-BI+/+). (D) Plasma TNF-α levels 2 hours after LPS
injection with or without corticosterone supplementation.
SR-BI+/+ and SR-BI–/– mice were injected i.p. with 0.5 and
5 μg/g body weight of LPS. Values shown are the mean
± SD (n = 4). *P < 0.05; **P < 0.01. Similar results were
found in 3 independent experiments.
The Journal of Clinical Investigation    http://www.jci.org    Volume 118    Number 1    January 2008
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Figure 4
Primary adrenal deficiency in SR-BI–/– mice. (A) Plasma ACTH levels
in SR-BI+/+ and SR-BI–/– male mice challenged with LPS (0.5 μg/g body
weight of LPS or saline) for 2 hours (B) ACTH-induced corticosterone
response in SR-BI+/+ and SR-BI–/– mice. Male SR-BI+/+ and SR-BI–/–
mice were injected with 2 U of ACTH s.c. and sacrificed under anesthesia at the indicated times. (C) Adrenal insufficiency in SR-BI–/– mice
under stress. Female SR-BI+/+ and SR-BI–/– mice were stressed by a
3-minute cold water (5°C) swim followed by a 17-minute rest at room
temperature. Values shown are mean ± SD (n = 4). Similar results
were found in 3 independent experiments. *P < 0.05; **P < 0.01.

SR-BI–null mice reached similar and possibly maximal levels at
the 2 LPS doses used, the responses of IL-6 and MCP-1 in control
mice were much lower at the lower LPS dose. These results are in
line with an enhanced sensitivity of SR-BI–null mice to low doses
of LPS. Overall, the results of this experiment show that adrenalectomy to a large extent abolished the differences in inflammatory cytokines between SR-BI–null and control mice.
LPS-treated adrenalectomized mice of both control and SR-BI–
null groups showed low levels of plasma corticosterone that were
similar to the levels in untreated SR-BI–null mice (Figure 6D).
These data further confirm the finding that a lack of SR-BI prevents LPS-induced production of corticosterone in adrenals. In
adrenalectomized mice, the levels of corticosterone were low but
significant and were higher in control than in SR-BI–null mice.
Extra-adrenal glucocorticoid synthesis has been reported (33), and
our results point to the possibility that such extra-adrenal synthesis may also be dependent on SR-BI. Together, these data suggest
that adrenal insufficiency plays a major role in contributing to
the enhanced LPS-induced inflammatory response in SR-BI–null

mice. At the same time, the significant difference between TNF-α
levels in adrenalectomized SR-BI–null and control mice supports a
conclusion that SR-BI influences inflammation by mechanisms in
addition to its role on adrenal glucocorticoid production.
To address the possible mechanisms for adrenal insufficiency in
SR-BI–null mice, we first examined ERK phosphorylation, a key
step in the ACTH-induced signaling pathway in the adrenals (35).
ERK phosphorylation to p-ERK was found to be induced by LPS
within 1 hour in adrenals to a similar extent in SR-BI–null mice
and control mice, with no significant changes in the levels of total
ERK during the same period (data not shown). This result is consistent with ACTH signaling in the adrenals being initiated in a normal manner by ACTH in SR-BI–null mice. Two key enzymes in the
biosynthesis of glucocorticoids that are transcriptionally induced
during stimulation of corticosterone production from cholesterol
are steroidogenic acute regulatory protein (StAR) and cytochrome
P450 side-chain cleavage enzyme (Cyp11A1) (29). StAR is required
for cholesterol transport across the inner mitochondrial membrane, and Cyp11A1 converts cholesterol into pregnenolone by
catalyzing cholesterol side-chain cleavage. In untreated mice, the
expression of both StAR and Cyp11A1 mRNA in adrenals was similar in SR-BI–null and control mice, as assessed by adrenal mRNA
levels (Figure 7, A and B). Expression of mRNA for both proteins
was upregulated by LPS within 1 hour in control mice and to at
least the same extent in SR-BI–null mice. mRNA levels for both
proteins remained higher in SR-BI–null mice compared with control mice for at least 24 hours. In line with StAR transcriptional

Figure 5
Hyperinflammatory response in SR-BI–/– mice challenged with E. coli.
SR-BI–/– and SR-BI+/+ mice were injected i.p. with 2 × 107 CFU E. coli
per mouse. Two hours after the injection, mice were sacrificed and
plasma was collected. (A) Plasma cytokine levels determined by
ELISA. (B) Plasma corticosterone levels determined by RIA. Values
shown are mean ± SD (n = 4). Similar results were found in 2 independent experiments. *P < 0.05; **P < 0.01.
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Figure 6
Effects of adrenalectomy on LPS-induced
response in SR-BI–/– and SR-BI+/+ mice.
Mice were adrenalectomized and allowed to
recover for 1 week. Adrenalectomized mice
(ADX) and sham-operated mice (sham)
were injected i.p. with LPS (0.125 μg/g body
weight), and 2 hours later, plasma cytokines
and corticosterone levels were determined.
(A) Plasma TNF-α levels. (B) Plasma IL-6
levels. (C) Plasma MCP-1 levels. (D) Plasma corticosterone levels. Values shown are
mean ± SD (n = 5). *P < 0.05; **P < 0.01.
Similar results were found in 3 independent
experiments.

upregulation, the levels of StAR protein in the adrenals were also
upregulated in both groups of mice and at least to the same extent
in SR-BI–null mice as in control mice (Figure 7C). These results
again suggest normal adrenal regulatory responses in respect to
ACTH signaling in SR-BI–null mice.
The availability of unesterified cellular cholesterol is a key determinant in corticosterone production (29). To assess whether the
inability of SR-BI–null mice to induce corticosterone synthesis in
SR-BI–null mice results from limited cholesterol availability in
the adrenal, we analyzed the expression of 2 proteins, the LDLR
and HMG-CoA reductase, whose expression at the transcriptional
level is highly regulated by the level of intracellular cholesterol
(25, 36). The LDLR serves to internalize LDL, and HMG-CoA
reductase is the key regulatory enzyme in cholesterol biosynthesis.

Adrenal mRNA levels for the 2 proteins were determined in control and SR-BI–null mice before and after LPS treatment (Figure
7, D and E). Basal LDLR mRNA levels were about 2-fold greater
in SR-BI–null than in control mice, indicative of decreased cellular cholesterol levels in SR-BI–null mice, as previously reported by
others (31) (Figure 7D). In the case of control mice, mRNA levels for LDLR were moderately increased (<2 fold) following LPS
treatment and returned to unstimulated levels within 24 hours.
In contrast, LPS induced a striking increase in LDLR mRNA levels
in SR-BI–null mice to levels that were about 4- to 5-fold higher
than those in control mice. Similarly, HMG-CoA reductase was
markedly upregulated (about 7-fold) in SR-BI–null mice but was
relatively unchanged in control mice following LPS treatment
(Figure 7E). The extensive transcriptional upregulation of these

Figure 7
Adrenal gene expression during LPS-induced inflammatory response. SR-BI+/+ and SR-BI–/– mice were injected i.p. with 0.5 μg/g body weight of
LPS. Mice were sacrificed at indicated time points, and adrenals were collected for mRNA extraction and Q-PCR. (A) Adrenal StAR mRNA. (B)
Adrenal Cyp11A1 mRNA. (C) Adrenal StAR Western blot (10 μg cell protein/lane). Mice were sacrificed 2 hours after LPS injection. Adrenals
were collected, and proteins were extracted. (D) Adrenal LDLR mRNA. (E) Adrenal HMG-CoA reductase mRNA. Values shown are mean ± SD
(n = 3) of the ratio of genes for the target genes to that of the 18S rRNA. Similar results were found in 2 independent experiments.
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Figure 8
SR-BI–dependent uptake of LPS in hepatocytes. (A) Primary
hepatocytes were washed and incubated with 5 μg/ml of Alexa
Fluor–LPS at 37°C for 1 hour in DMEM medium containing 0.5% BSA.
Fluorescence microscopy was performed at ×40 original magnification with equal exposures (Alexa Fluor–LPS, red; DAPI, blue, nuclear stain). (B) Association of lipid-free and HDL-bound 125I-LPS with
SR-BI+/+ and SR-BI–/– primary hepatocytes. Where indicated (LPS +
HDL), 125I-LPS (5 μg) was preincubated with human HDL3 (10 μg) at
room temperature for 30 minutes before addition to cells. Hepatocytes
were incubated with 5 μg/ml 125I-LPS or 125I-LPS + HDL at 37°C for
1 hour in DMEM medium containing 0.5% BSA. Values shown are the
mean ± SD of triplicate determinations (*P < 0.05). Similar results were
found in 4 independent experiments.

2 proteins by LPS in SR-BI–null mice indicates that, following
LPS treatment, there is a rapid and marked decrease in cellular
unesterified cholesterol, presumably due to an inability of cells to
replenish intracellular cholesterol from circulating lipoproteins,
intracellular biosynthesis, or cellular CE stores. Recent studies
suggest that the cholesterol transporter ABCA1 may also contribute to adrenal cholesterol regulation (37). We evaluated adrenal
ABCA1 expression in mice in response to LPS and found that both
ABCA1 mRNA and protein levels were significantly lower in SR-BI–
null mice, suggesting that ABCA1 did not contribute to low cellular cholesterol levels in these mice (data not shown).
We conclude from these results that SR-BI in the adrenals is
required to provide, through the process of selective CE uptake,
sufficient cholesterol for glucocorticoid production under conditions of high adrenal stimulation by ACTH, such as occurs during
LPS-induced inflammation.
SR-BI plays a role in LPS clearance into hepatocytes. Since LPS is cleared
largely via hepatocytes (8), which express high levels of SR-BI,
and since SR-BI functions as a receptor for both HDL and LPS,
we investigated whether SR-BI is responsible for LPS clearance by
the liver. Cultured primary hepatocytes were isolated from control
and SR-BI–null mice and assayed for their ability to take up LPS.
As shown in Figure 8A, fluorescently labeled Alexa Fluor–LPS was
taken up rapidly within 1 hour into control hepatocytes but to a
significantly lesser extent in SR-BI–null hepatocytes. Similarly, cell
association of 125I-LPS was decreased in SR-BI–null hepatocytes

(Figure 8B). Interestingly, SR-BI can mediate 125I-LPS uptake
more efficiently when LPS is in its HDL-associated form. While
the uptake of LPS is reduced in SR-BI–null hepatocytes, a significant level of SR-BI–independent uptake was observed, suggesting
the involvement of other candidate receptors, such as SR-A, in
this process. The clearance of 125I-LPS from plasma and its uptake
into the liver was also investigated in control and SR-BI–null mice.
First, the uptake of 125I-LPS into hepatocytes and nonhepatocytes
isolated from livers collected 2 hours after LPS injection was measured. In line with the uptake of Alexa Fluor–LPS in cultured
hepatocytes (Figure 8A), uptake of 125I-LPS was significantly lower
(by approximately 50%) in the hepatocytes, but not nonhepatocytes, of SR-BI–null mice compared with control mice (Figure 9A).
Thirty minutes following injection, 125I-LPS uptake into the liver
of SR-BI–null mice was significantly lower (by approximately 40%)
than in control mice (Figure 9B). In contrast, uptake of 125I-LPS
into the spleen and kidney was similar in the 2 animal groups (Figure 9B). In line with the reduced uptake of 125I-LPS into the liver
of SR-BI–null mice, 125I-LPS remaining in plasma was greater in
SR-BI–null mice. We conclude from these results that hepatic
SR-BI expressed in hepatocytes plays a major physiologically significant role in clearance of LPS from plasma.
To assess whether the observed differences between control and
SR-BI–null mice in response to LPS might be related to previously

Figure 9
LPS distribution in the liver. (A) LPS distribution in hepatocytes and
nonhepatocytes. 125I-LPS (0.125 μg/g body weight) was injected
through the tail vein into SR-BI–/– and SR-BI+/+ mice. After 2 hours,
mice were sacrificed and hepatocytes and nonhepatocytes were isolated. (B) LPS tissue distribution. 125I-LPS (0.125 μg/g body weight) was
injected through the tail vein into SR-BI–/– and SR-BI+/+ mice. Plasma,
liver, kidney, and spleen were collected after 30 minutes. LPS distribution was calculated as percentage of the total injected LPS dose.
Values shown are the mean ± SD (n = 4). *P < 0.05. Similar results
were found in 3 independent experiments.
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Figure 10
Plasma from SR-BI+/+ and SR-BI–/– mice showed similar LPS neutralization activity. Plasma (1 μl) from SR-BI+/+ and SR-BI–/– mice (pooled
from 4 mice in each group) was incubated with different amounts of
LPS (10 ng, 25 ng, 50 ng, and 100 ng) at 37°C for 1 hour. Endotoxin
activities relative to no-plasma controls at each LPS concentration
(percentage of neutralization) were determined by using a commercially available LAL assay kit. Similar results were found in 3 independent experiments.

described differences in HDL levels or HDL structure or composition in the 2 mouse strains, we analyzed plasma lipoprotein profiles in mice before and after LPS treatment. As previously reported, plasma HDL cholesterol levels were elevated more than 2-fold
in SR-BI–null mice compared with control mice (38), and the HDL
particles in SR-BI–null mice were abnormally large and contained
a higher content of free cholesterol (31) (data not shown). An LPS
challenge lowered HDL cholesterol levels in both SR-BI–null mice
and the control mice: SR-BI–/– basal, 220.6 ± 4.8 μg/dl, vs. SR-BI–/–
plus LPS, 158.5 ± 14.5 μg/dl (P < 0.05); SR-BI+/+ basal, 79.1 ± 8.3 μg/dl,
vs. SR-BI+/+ plus LPS, 57.3 ± 8.1 mg/dl (P < 0.05). Free cholesterol was
also decreased to a similar extent between the 2 mouse strains: SR-BI–/–
basal, 86.9 ± 4.36 μg/dl, vs. SR-BI–/– plus LPS, 69.2 ± 3.92 μg/dl
(P < 0.05); SR-BI+/+ basal, 24.5 ± 1.89 μg/dl, vs. SR-BI+/+ plus LPS,
17.9 ± 0.57 μg/dl (P < 0.05). A Limulus amebocyte lysate (LAL)
assay was used to measure the neutralizing effect of lipoprotein
from SR-BI–null mice and control mice. No difference in plasma
LPS neutralization was found between the 2 genotypes (Figure 10).
This indicates that HDL from SR-BI–null mice, like control mice,
is able to bind and neutralize LPS effectively.
Discussion
The present study demonstrates that SR-BI–null mice exhibit
an enhanced inflammatory response to LPS as shown by highly
elevated levels of inflammatory cytokines compared with control
mice and decreased survival when challenged with endotoxin. This
occurs despite the elevated levels of HDL in these mice, which is
normally protective against LPS-induced inflammation. Strikingly, SR-BI–null mice failed to show any significant induction of
corticosterone production in response to LPS. A lack of glucocorticoid stimulation was also observed in these mice in response to
exogenous ACTH, indicating that the glucocorticoid insufficiency
is not due to impaired signaling in the hypothalamic-pituitaryadrenal axis upstream of the adrenals but rather is the result of primary adrenal deficiency due to an inadequate cholesterol supply.
In addition to its role in glucocorticoid production, our results
show that SR-BI also plays a role in the clearance of plasma LPS.
Our findings that corticosterone supplementation in SR-BI–null
mice exerts a major protective effect against endotoxin-induced

death provides strong support for a key protective role for glucocorticoids in endotoxin-induced death. Glucocorticoids act to
efficiently limit the inflammatory response (39), and stimulation
of glucocorticoid production by the adrenals has generally been
considered a key component in host defense against severe inflammation and endotoxic shock (27). Our results further point to the
strong possibility that SR-BI protects against endotoxemia in part
through its role in glucocorticoid biosynthesis. However, since
pharmacological doses of glucocorticoids have been shown to be
protective even in the absence of adrenal insufficiency (28), it is
possible that glucocorticoid supplementation at the relatively high
levels reached in the SR-BI–null mice protects against endotoxemia
in a manner unrelated to the adrenal insufficiency present in these
mice. Since endotoxic shock is often associated with low levels of
glucocorticoids, glucocorticoids have long been used in the management of sepsis and shown to efficiently limit uncontrollable
inflammation (1). However, the concept of adrenal deficiency during sepsis is complex and is still in some doubt (28). Clinical trials,
for example, have not shown survival benefit with the early use of
high-dose corticosteroids in adrenally intact patients with severe
sepsis (1). On the other hand, survival benefit was seen in a group
of adrenally insufficient patients that did not respond to a corticotropin-stimulation test (28), and further clinical studies on the
role of glucocorticoids in sepsis are therefore required.
During the acute phase of inflammatory response, the increased
secretion of corticosterone depends on increased synthesis, a
complex process involving a number of key regulatory steps. Our
results show a normal increase in ACTH levels in SR-BI–null mice in
response to LPS as well as a typical adrenal response to ACTH. Thus,
LPS induced plasma levels of ACTH similar to those in control mice
and also triggered typical ERK phosphorylation in the adrenals. Two
other key regulatory proteins were shown to respond to stimulation
of SR-BI–null mice similarly to control mice. StAR, which is required
for cholesterol transport to the inner leaflet of mitochondria (29),
and Cyp11A1, the side-chain cleavage enzyme responsible for pregnenolone formation (29), are both upregulated in adrenals in SR-BI–
null mice as in control mice. Together, our data indicate normal
ACTH release and consequent signaling in the adrenals in response
to LPS and point to insufficient uptake of cholesterol required for
glucocorticoid synthesis in SR-BI–null mice.
Corticosterone synthesis is dependent on an adequate supply of
cholesterol to the adrenal cortex zona fasciculata cells. Cholesterol
for steroid synthesis is derived largely from plasma lipoproteins in
animals as well as humans (25, 40). Previous studies have shown
that cholesterol can be taken up from HDL by SR-BI in the form
of esterified and free cholesterol, although CEs likely contribute
to the majority of uptake (20, 41, 42). Cholesterol is also taken up
from LDL by both the LDLR (23) and SR-BI (22, 43). However, HDL
appears to be the more important source of cholesterol (24, 30).
Consequently, apoA-I–null mice with low plasma HDL fail to accumulate CE in the adrenals and were shown to have a reduced glucocorticoid response to a swim stress test or ACTH challenge (30).
Although SR-BI–null mice were found to have no gross phenotypic
alterations, it was not clear whether these animals had an altered
steroidogenic response (10). Our results show that during severe
stress such as occurs in the response to LPS, SR-BI is absolutely
required for enhanced corticosterone synthesis. Moreover, in addition to its role in the response to bacterial LPS, SR-BI was shown to
be required for a normal glucocorticoid response to the conditions
of a swim stress test. Thus, the critical role of SR-BI is not limited
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Table 2
Q-PCR primer sequences

Although the effect of LPS on SR-BI regulation in the adrenals is not known, downregulation of SR-BI would reduce cholesterol supply to the adrenal and may lead to decreased
Gene
Accession
Primers
NT location
number		
(size, bp)A
glucocorticoid production. Furthermore, the
inflammatory response is typically characterLDLR
Z-19521
5′-AGGCTGTGGGCTCCATAGG-3′
1181–1252
		
5′-TGCGGTCCAGGGTCATCT-3′
(72)
ized by a relatively rapid reduction in plasma
HMG-CoA
NM_008255
5′-CTTGTGGAATGCCTTGTGATTG-3′
578–653
levels of HDL cholesterol and apoA-I (46).
reductase		
5′-AGCCGAAGCAGCACATGAT-3′
(76)
Although the mechanisms responsible for
TNF-α
NM_013693
5′-GGCAGGTCTACTTTGGAGTCATTG-3′
833–970
this rapid decline in HDL remain uncertain,
		
5′-GTTAGAAGGATACAGACTGG-3′
(138)
reduced HDL levels would also be expected
IL-6
NM_031168
5′-CAACGATGATGCACTTGCAG-3′
265–400
to decrease SR-BI–mediated HDL cholesterol
		
5′-GTAGCTATGGTACTCCAGAAG-3′
(136)
delivery to the adrenals. The combined effects
StAR
NM_011485
5′-TTGGGCATACTCAACAACCA-3′
312–414
of reduced HDL and SR-BI during inflamma		
5′-GAAACACCTTGCCCACATCT-3′
(103)
tion may thus lead to significant reductions in
CYP11A1
NM_019779
5′-CGAGACTTCAGCCAGTACCC-3′
906–1003
glucocorticoid production.
		
5′-GCCAGCATCTCGGTAATGTT-3′
(98)
ABCA1
NM_013454
5′-AGCCAGAAGGGAGTGTCAGA-3′
2955–3056
Our finding that corticosterone supplemen		
5′-CATGCCATCTCGGTAAACCT-3′
(102)
tation did not completely normalize endotoxin-induced death in SR-BI–null mice, together
ANumbers without parentheses refer to primer location on the gene, while numbers within
with the fact that adrenalectomy did not comparentheses refer to PCR product size.
pletely abolish the difference in TNF-α response
between SR-BI–null and control mice, indicates
to the response of the foreign inflammatory agent LPS but is also that SR-BI exerts other nonadrenal protective functions. SR-BI–null
important in the glucocorticoid response to physical and mental mice have abnormally large cholesterol-rich HDL particles due to
stress unrelated to bacterial infection.
defective HDL CE clearance (31). The apoA-I levels in normal and
The cholesterol supply in adrenals is potentially derived from 3 SR-BI–null mice are similar, suggesting that the number of HDL
main sources, namely (a) CE from circulating HDL or LDL, (b) CE particles in the 2 mouse strains are also similar. Since lipoproteins
from CE droplets present in cells, and (c) endogenous cholesterol such as LDL (5) and HDL (47) have strongly protective effects
synthesis. While cholesterol synthesis may provide sufficient cho- through their ability to neutralize LPS, we investigated whether an
lesterol for basal corticosterone synthesis, our results in SR-BI–null enhanced susceptibility of SR-BI–null mice to LPS might be due to
mice show that, under conditions of high demand, endogenous an inability of the abnormal HDL in these mice to neutralize LPS.
synthesis is unable to support increased corticosterone production. Our results, however, showed that the total LPS neutralizing activThis occurs despite a marked induction of HMG-CoA reductase, ity of plasma from SR-BI–null and control mice was similar, thus
the key regulatory enzyme in cholesterol biosynthesis. Similarly, showing effective binding and neutralization in both cases.
despite its marked upregulation, the LDLR was also unable to supEarlier studies have shown that LPS, either in lipid-free form or
port enhanced corticosterone production in these mice. This is in when associated with HDL, is bound and internalized by SR-BI in
line with earlier findings that corticosterone production in LDLR- HeLa cells and macrophages (15). On this basis, SR-BI might facilinull mice is unimpaired (25). Our results clearly demonstrate that tate LPS clearance into hepatocytes, thereby decreasing the LPS
SR-BI–mediated selective CE uptake is essential for enhanced corti- burden. Our findings demonstrate that SR-BI indeed contributes
costerone production. The CE taken up by SR-BI serves as a source significantly to LPS uptake into hepatocytes and to LPS clearance
of cholesterol in CE droplets found in adrenocortical cells, as previ- into the liver. In the case of nonhepatocytes, no significant differously shown by the reduced cellular CE content in apoA-I–null and ence was found in LPS association between control cells and SR-BI–
also SR-BI–null mice (10, 30). Such droplets are considered to be null cells. Although earlier studies have pointed to the ability of
short-term stores of cholesterol for glucocorticoid synthesis, since Kupffer cells to take up and detoxify LPS, the mechanisms for this
they are rapidly depleted under ACTH stimulation (40). CE taken are ill-defined (8). However, our results suggest that the stimulaup by SR-BI may also be used more directly for glucocorticoid syn- tion of inflammatory cytokines by LPS in Kupffer cells does not
thesis following its uptake and rapid hydrolysis by hormone-sen- depend on the ability of SR-BI to bind or internalize LPS, as has
sitive lipase (41). Hormone-sensitive lipase plays a key role in the been reported in the case of the THP-1, a human monocyte cell
hydrolysis of CE delivered to cells by SR-BI as well as CE stored in line (48). Thus, while SR-BI may serve other protective and antiinCE droplets (25). Although the SR-BI–null mice used in this study flammatory functions, these occur within the context of a powerlack both SR-BI and SR-BII isoforms, SR-BI likely contributes to ful glucocorticoid response to LPS and proper clearance of LPS
the vast majority of CE uptake, since SR-BII is expressed at low lev- through the hepatocytes.
els in the adrenals compared with SR-BI and is also less active in
Sepsis is a complex process that can be divided into an early
cholesterol uptake than SR-BI (17).
hyperinflammatory response stage that induces acute organ dysThe critical role of SR-BI in glucocorticoid production suggests function and a later hypoinflammatory stage associated with
that downregulation of SR-BI–mediated HDL cholesterol delivery immunosuppression (1). Treatment of sepsis is complicated,
to the adrenals may be a mechanism contributing to glucocorti- given the opposing natures of these 2 stages. Our findings suggest
coid insufficiency, which is often observed during sepsis. During that SR-BI exerts protective functions throughout the process of
the inflammatory response to endotoxin, SR-BI has been shown sepsis, first by allowing a normal glucocorticoid response in the
to be downregulated in hepatocytes (44) and macrophages (45). early hyperinflammatory stage and second, by limiting the LPS
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burden during both stages by promoting LPS clearance. A recent
study has reported that SR-BI protects against endotoxin-induced
death by preventing NO-induced cytotoxicity (19). NO generation
is induced during septic shock and contributes significantly to the
symptoms of septic shock. Our results suggest that the glucocorticoid insufficiency seen in SR-BI–null mice might lead to enhanced
endotoxic shock since glucocorticoids are known to inhibit NO
production in a wide variety of cells (49). In the study by Li et al.,
however, NO levels in SR-BI–null mice were shown to be only
moderately increased by LPS compared with control mice and the
authors concluded that SR-BI prevents NO-induced cytotoxicity
by mechanisms unrelated to NO synthesis (19).
Our data raise the possibility that the known protective role of
SR-BI against atherosclerosis may be related to its antiinflammatory function. SR-BI–null mice and combined SR-BI/LDLR
double-knockout mice on high-fat diets show accelerated atherosclerotic lesion development compared with control mice (50,
51). SR-BI/apoE–double-knockout mice not only develop atherosclerotic plaques but also have severe cardiac malfunction that
includes spontaneous myocardial infarction and cardiac failure
(52). Clearly, the lack of proper hepatic HDL cholesterol clearance will have significant effects in these SR-BI–null models.
Nevertheless, our findings suggest that an enhanced inflammatory response may also contribute to atherogenesis in SR-BI–null
mice. In SR-BI–null mice, for example, we show that chemokines
produced in macrophages and vascular cells, such as MCP-1 and
RANTES, are markedly upregulated during inflammation. These
chemokines have been reported to promote the initiation of
plaque formation (53, 54). Studies using these models will need
to take cognizance of possible effects of altered adrenal function.
Furthermore, SR-BI may also play important roles in the clearance of endogenous proinflammatory reagents, including modified lipoproteins, such as oxidized LDL and other proinflammatory lipids, and pathogens. In contrast, mice lacking the class B
scavenger receptor CD36, which reportedly can also clear LPS in
vitro (18), did not show the exaggerated inflammatory response
to LPS seen in SR-BI–null mice. In fact, although CD36-null macrophages showed a reduced cytokine response to LPS and E. coli
challenge, CD36 deficiency in mice did not protect them from
E. coli–induced lethality (55).
In summary, we demonstrate that SR-BI–mediated cholesterol
delivery to the adrenals is essential for an effective antiinflammatory glucocorticoid response to LPS or stress and SR-BI regulates
LPS-induced inflammation and endotoxic shock. SR-BI serves a
protective function in mediating LPS clearance from the plasma.
Methods
Animals and reagents. SR-BI–deficient mice (SR-BI null) were obtained from
M. Krieger (Massachusetts Institute of Technology, Cambridge, Massachusetts, USA) (31). These mice lack both functional SR-BI and SR-BII. SR-BI
homozygous (SR-BI–/–) mutant mice and control mice (both 1:1 mixed
C57BL/6 × 129 backgrounds) were bred from 2 lines generated from a
common mating pair of SR-BI heterozygous (SR-BI–/+) mice. Since female
SR-BI–/– mice are infertile, SR-BI–/– mice were bred using SR-BI–/– male and
SR-BI–/+ female mice. For all animal experiments, 8- to 12-week-old male
and female mice, weighing 20–25 g, were used. All animal experiments were
approved by the Veterans Affairs Medical Center, Institutional Animal Care
and Use Committee.
LPS (E. coli serotype 0111:B4; 1 × 106 endotoxin units/mg LPS) was
obtained from Sigma-Aldrich. Corticosterone and ACTH 125-I RIA assay

kits were obtained from MP Biomedical. TNF-α and IL-6 ELISA kits were
from R&D Systems, MCP-1 ELISA set was from BD Diagnostics, and the
LAL assay kit was obtained from Cape Cod Inc.
E. coli (ATCC25922; ATCC) were cultured in Luria-Bertani broth and
tryptic soy broth (ATCC) at 37°C using standard procedures and harvested
at mid-log phase, which reached OD660= 5.0 (~2 × 108 CFUs/ml). Bacteria
were washed twice, suspended in sterile saline, and injected i.p. into mice
(2 × 107 CFUs E. coli/100 μl saline).
Corticosterone and ACTH determination. Plasma was isolated from blood
obtained from SR-BI–null or control mice. Samples were assayed immediately to avoid degradation. Corticosterone levels and ACTH in the plasma
were determined using specific radioimmunoassay kits (125I-RIA kit for
ACTH and corticosterone; MP Biomedicals).
Cytokine determination. Serum was isolated from the blood of SR-BI–
null and control mice and immediately frozen at –80°C. Cytokine levels
were determined by multiplex biomarker assay using xMAP technology
by Linco Diagnostic Services Inc. Cytokine values were calculated using
standard concentration curves determined for each cytokine on each 96well plate used. Plasma TNF-α levels and IL-6 levels were also determined
using ELISA kits from R&D systems; MCP-1 was determined using ELISA
sets from BD Diagnostics.
Q-PCR. Total RNA was isolated from mouse liver and adrenals using
the standard TRIzol method (Invitrogen). RNA was further purified with
DNase I (Roche) and RNeasy Mini Kit (QIAGEN). 2 μg of RNA was reverse
transcribed into cDNA using a reverse-transcription system (Promega).
After 4-fold dilution, 5 μl was used as a template for Q-PCR. Primers used
in this study are listed in Table 2. Amplification was done for 40 cycles
using Power SYBR Green PCR master Mix Kit (Applied Biosystem) and
DNA Engine Optical 2 System (MJ Research Inc.). Both internal control
(18S rRNA) and negative control (minus reverse transcriptase) were included. Values of each RNA sample were the average of duplicate assays normalized toward 18S rRNA (internal control) levels.
125I radioiodination and Alexa Fluor labeling of LPS. LPS was iodinated by the
chloramine T method (56). In brief, 1 mg of LPS was dissolved in 0.05 M
borate buffer (pH = 8) and incubated with 50 mM pOH methylbenzimidate at 37°C for 18 hours. After extensive dialysis, the M-LPS was radiolabeled with Na125I by the chloramine T method. After iodination, the
unincorporated Na125I was removed by extensive dialysis against sterile
saline at 4°C. For fluorescent labeling of LPS, 1 mg of LPS was incubated
with 1 vial of Alexa Fluor 488 dye (Invitrogen) in 0.1 M sodium borate
buffer (pH = 10.5) for 3 hours at 37°C. After incubation, the mixture
was dialyzed exhaustively against 4 liters of 150 mM NaCl with at least
6 changes. The bioactivity of labeled LPS was determined by the LAL
assay kit. Near-identical bioactivity was observed among unlabeled LPS,
125-I-LPS, and Alexa Fluor–LPS.
LPS neutralization assay. Lipoproteins were preincubated with various
amounts of LPS at 37°C for 1 hour, after which LAL activity of LPS
was quantitatively determined according to the manufacturer’s instructions. The analytical sensitivity of the kit is 0.005 EU/ml (0.5 pg of
highly purified LPS/ml).
Primary hepatocyte isolation and culture. The isolation of primary
hepatocytes and nonhepatocytes was performed as described earlier (57)
with certain modifications. In brief, livers were minced and dissociated in
collagenase containing medium at 37°C for 10–12 minutes. Cell suspensions were filtered through mesh (100 μm) and spun down. Hepatocytes
were collected after a first spin (50 g for 2 minutes), while the nonhepatocytes were collected after a second spin (500 g for 10 minutes). Hepatocytes
were washed twice in HBSS and suspended in enriched Williams’ E Medium (GIBCO; Invitrogen). Viable cells were counted and plated in 24-well
mouse collagen IV–coated plates (Fisher).
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LPS uptake into primary hepatocytes. Cell association assays were performed
as described previously (13). In brief, primary hepatocytes were seeded into
24-well cell culture clusters at an initial density of 1 × 105 cells/cm2. When
cells reached confluency, they were washed with phosphate-buffered saline
and incubated at 37°C for 2 hours with 125I-LPS in DMEM medium containing 0.5% essentially fatty acid free albumin (BSA). After incubation,
medium was removed and the cells were washed 4 times with cold buffer
(50 mM Tris-HCl, 150 mM NaCl, pH 7.4) containing BSA (2 mg/ml) followed by 2 washes in the same buffer without BSA. The cells were then
solubilized in 0.1 N NaOH for 1 hour at room temperature, and the protein and 125I content of the lysate were determined.
Adrenalectomy. SR-BI–null and control mice were adrenalectomized following standard surgical procedures (58). Following surgery, mice were
placed in individual clean cages and allowed to recover for 1 week while
maintained on normal chow diet and drinking water containing 0.9% sodium chloride. Sham-operated control mice underwent the same surgical
procedure as adrenalectomized groups, except their adrenal glands were
not excised. Experiments were performed 1 week after surgery. Sham-operated and test mice were injected i.p. with LPS and sacrificed 2 hours later.
Survival determination. SR-BI–/– mice, SR-BI+/– mice, and SR-BI+/+ mice
were injected i.p. with 5 μg/g body weight of LPS. In some experiments,
SR-BI–/– mice were given corticosterone (Sigma-Aldrich), initially dissolved
in ethanol, in their drinking water (100 μg/ml) starting 8 hours prior to
LPS injection. In these experiments, control groups were given an equivalent amount of vehicle only (0.1% ethanol) in their drinking water. Mice
were allowed to eat and drink freely. Mice were under careful observation
for behavior and survival during the following 3 days.
Swim stress test and ACTH treatment. For the stress test, female mice were
placed in 5°C water and forced to swim for 3 minutes (59). Following the
swim, mice were rested at room temperature for 17 minutes prior to sacrifice. Blood was taken for corticosterone and ACTH determination. For
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